Metastatic Breast Cancer

DESTINY-Breast06: results support the use of trastuzumab deruxtecan in earlier lines of treatment for patients with metastatic breast cancer

Recently published in The New England Journal of Medicine, results from the phase 3, multicenter DESTINY-06 clinical trial show that…

Novel AKT inhibitor combined with standard hormone therapy shows promise for patients with pre-treated metastatic HR+/ HER2- breast cancer

Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…